Deferiprone
- Generic Name
- Deferiprone
- Brand Names
- Ferriprox, Deferiprone Lipomed
- Drug Type
- Small Molecule
- Chemical Formula
- C7H9NO2
- CAS Number
- 30652-11-0
- Unique Ingredient Identifier
- 2BTY8KH53L
- Background
Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA approved on October 14, 2011.
- Indication
Deferiprone is indicated in thalassemia syndromes when first line chelation agents are not adequate to treat transfusional iron overload.
- Associated Conditions
- Transfusional Iron Overload
- Associated Therapies
- -
A Study Investigating the Safety and Tolerability of Deferiprone in Patients With Friedreich's Ataxia
- First Posted Date
- 2007-09-17
- Last Posted Date
- 2010-06-02
- Lead Sponsor
- ApoPharma
- Target Recruit Count
- 80
- Registration Number
- NCT00530127
- Locations
- 🇦🇺
Murdoch Children's Research Institute, Victoria, Australia
🇧🇪Hospital Erasme, Brussels, Belgium
🇪🇸La Fundacion Para la Investigacion Biomedica, Madrid, Spain
Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients
- First Posted Date
- 2007-09-14
- Last Posted Date
- 2009-09-02
- Lead Sponsor
- ApoPharma
- Target Recruit Count
- 100
- Registration Number
- NCT00529152
- Locations
- 🇪🇬
Children Hospital, Ain Shams University, Cairo, Egypt
🇮🇩Cipto Mangunkusumo National Hospital, Jakarta, Indonesia
🇲🇾University of Malaya Medical Center, Kuala Lumpur, Malaysia
Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease
- Conditions
- First Posted Date
- 2006-02-17
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- Children's Hospital of Philadelphia
- Registration Number
- NCT00293098
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Combined Chelation Treatment With Deferiprone and Deferoxamine in Thalassemia Major
- Conditions
- First Posted Date
- 2005-02-15
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
- Target Recruit Count
- 65
- Registration Number
- NCT00103753
- Locations
- 🇮🇹
Ospedale Microcitemico, Via Jenner, Cagliari, Sardinia, Italy
Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Carelon Research
- Target Recruit Count
- 1000
- Registration Number
- NCT00000623
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Weill Medical College of Cornell University, New York, New York, United States
🇺🇸Children's Hospital Oakland, Oakland, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.